{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:23:10Z","timestamp":1776248590191,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00198-025-07825-2","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T06:42:22Z","timestamp":1769409742000},"page":"727-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset"],"prefix":"10.1007","volume":"37","author":[{"given":"Rohit","family":"Vijjhalwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7359-5506","authenticated-orcid":false,"given":"Kaiyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Clemeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"Sanchez-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhuvan","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Bowcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Delmestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Pinedo-Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"7825_CR1","unstructured":"Cancer Research UK [Internet]. Myeloma incidence statistics. Date accessed: 31 August 2023. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence."},{"key":"7825_CR2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041131","author":"LJ Melton","year":"2005","unstructured":"Melton LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV (2005) Fracture risk with multiple myeloma: a population\u2010based study*. J Bone Miner Res. https:\/\/doi.org\/10.1359\/JBMR.041131","journal-title":"J Bone Miner Res"},{"key":"7825_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C et al (2016) Multiple myeloma: patient outcomes in real\u2010world practice. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"key":"7825_CR4","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp15X683545","author":"EA Shephard","year":"2015","unstructured":"Shephard EA, Neal RD, Rose P, Walter FM, Litt EJ, Hamilton WT (2015) Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case\u2013control study using electronic records. Br J Gen Pract. https:\/\/doi.org\/10.3399\/bjgp15X683545","journal-title":"Br J Gen Pract"},{"key":"7825_CR5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230011","author":"S Thorsteinsdottir","year":"2019","unstructured":"Thorsteinsdottir S, Gislason G, Aspelund T et al (2019) Fractures and survival in multiple myeloma: results from a population-based study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.230011","journal-title":"Haematologica"},{"issue":"3","key":"7825_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsdottir K, Harvey NC et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775\u201380","journal-title":"Osteoporos Int"},{"issue":"6","key":"7825_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","volume":"28","author":"C Roux","year":"2017","unstructured":"Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28(6):1765\u20131769","journal-title":"Osteoporos Int"},{"issue":"8","key":"7825_CR8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Oden A et al (2018) Characteristics of recurrent fractures. Osteoporos Int 29(8):1747\u201357","journal-title":"Osteoporos Int"},{"key":"7825_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K et al (2015) Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. https:\/\/doi.org\/10.1093\/ije\/dyv098","journal-title":"Int J Epidemiol"},{"key":"7825_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1770","author":"S Dav\u00e9","year":"2009","unstructured":"Dav\u00e9 S, Petersen I (2009) Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf. https:\/\/doi.org\/10.1002\/pds.1770","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7825_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1557(200009\/10)9:5<359::AID-PDS507>3.0.CO;2-E","author":"TPV Staa","year":"2000","unstructured":"Staa TPV, Abenhaim L, Cooper C, Zhang B, Leufkens HGM (2000) The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf. https:\/\/doi.org\/10.1002\/1099-1557(200009\/10)9:5<359::AID-PDS507>3.0.CO;2-E","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7825_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2023.101291","author":"A Delmestri","year":"2023","unstructured":"Delmestri A, Prieto-Alhambra D (2023) Curator \u2013 a data curation tool for clinical real-world evidence. Inform Med Unlocked. https:\/\/doi.org\/10.1016\/j.imu.2023.101291","journal-title":"Inform Med Unlocked"},{"key":"7825_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2595","author":"S Hawley","year":"2016","unstructured":"Hawley S, Javaid MK, Rubin KH et al (2016) Incidence and predictors of multiple fractures despite high adherence to oral bisphosphonates: a binational population\u2010based cohort study. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.2595","journal-title":"J Bone Miner Res"},{"key":"7825_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(23)00285-4","author":"E Buzasi","year":"2024","unstructured":"Buzasi E, Carreira H, Funston G et al (2024) Risk of fractures in half a million survivors of 20 cancers: a population-based matched cohort study using linked English electronic health records. Lancet Healthy Longev. https:\/\/doi.org\/10.1016\/S2666-7568(23)00285-4","journal-title":"Lancet Healthy Longev"},{"key":"7825_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez127","author":"G Nador","year":"2019","unstructured":"Nador G, Ramasamy K, Panitsas F, Pratt G, Sadler R, Javaid MK (2019) Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kez127","journal-title":"Rheumatology"},{"key":"7825_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-06233-6","author":"G Agarwal","year":"2021","unstructured":"Agarwal G, Milan C, Mohsin Z et al (2021) Multiple myeloma screening within a fracture liaison service (FLS). Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-021-06233-6","journal-title":"Osteoporos Int"},{"key":"7825_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06870-z","author":"JA Kanis","year":"2023","unstructured":"Kanis JA, Johansson H, McCloskey EV et al (2023) Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-023-06870-z","journal-title":"Osteoporos Int"},{"key":"7825_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4502-0","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Od\u00e9n A et al (2018) Characteristics of recurrent fractures. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-018-4502-0","journal-title":"Osteoporos Int"},{"key":"7825_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2015.12.014","author":"R Xiao","year":"2016","unstructured":"Xiao R, Miller JA, Margetis K et al (2016) Predicting the progression of vertebral fractures in patients with multiple myeloma. Spine J. https:\/\/doi.org\/10.1016\/j.spinee.2015.12.014","journal-title":"Spine J"},{"key":"7825_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3953","author":"E Toth","year":"2020","unstructured":"Toth E, Banefelt J, \u00c5kesson K, Sp\u00e5ngeus A, Orts\u00e4ter G, Libanati C (2020) History of previous fracture and imminent fracture risk in Swedish women aged 55 to 90\u2009years presenting with a fragility fracture. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.3953","journal-title":"J Bone Miner Res"},{"key":"7825_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4732-1","author":"A Balasubramanian","year":"2018","unstructured":"Balasubramanian A, Zhang J, Chen L et al (2018) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-018-4732-1","journal-title":"Osteoporos Int"},{"key":"7825_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-06077-0","author":"S Khalid","year":"2021","unstructured":"Khalid S, Reyes C, Ernst M et al (2021) One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-021-06077-0","journal-title":"Osteoporos Int"},{"key":"7825_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac141","author":"KM Kim","year":"2022","unstructured":"Kim KM, Lui L-Y, Cummings SR (2022) Recent fall and high imminent risk of fracture in older men and women. Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afac141","journal-title":"Age Ageing"},{"key":"7825_CR24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2684","author":"O Sezer","year":"2003","unstructured":"Sezer O, Heider U, Zavrski I, K\u00fchne CA, Hofbauer LC (2003) Rank ligand and osteoprotegerin in myeloma bone disease. Blood. https:\/\/doi.org\/10.1182\/blood-2002-09-2684","journal-title":"Blood"},{"key":"7825_CR25","doi-asserted-by":"crossref","unstructured":"Mukkamalla SKR, Malipeddi D (2021)\u00a0 Myeloma bone disease: a comprehensive review. Int J Mol Sci\u00a0 22(12):6208.","DOI":"10.3390\/ijms22126208"},{"key":"7825_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3211","author":"GJ Morgan","year":"2013","unstructured":"Morgan GJ, Davies FE, Gregory WM et al (2013) Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3211","journal-title":"Clin Cancer Res"},{"key":"7825_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30072-X","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W et al (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(18)30072-X","journal-title":"Lancet Oncol"},{"key":"7825_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100999","author":"M Hussain","year":"2023","unstructured":"Hussain M, Khan F, Hadidi SA (2023) The use of bone-modifying agents in multiple myeloma. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2022.100999","journal-title":"Blood Rev"},{"key":"7825_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4809","author":"MK Simic","year":"2023","unstructured":"Simic MK, Mohanty ST, Xiao Y et al (2023) Multi\u2010targeting DKK1 and LRP6 prevents bone loss and improves fracture resistance in multiple myeloma. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.4809","journal-title":"J Bone Miner Res"},{"key":"7825_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"7825_CR31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-773341","author":"MM McDonald","year":"2017","unstructured":"McDonald MM, Reagan MR, Youlten SE et al (2017) Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. https:\/\/doi.org\/10.1182\/blood-2017-03-773341","journal-title":"Blood"},{"key":"7825_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694786","author":"N Lendvai","year":"2016","unstructured":"Lendvai N, Yee AJ, Tsakos I et al (2016) Phase IB study of cabozantinib in patients with relapsed and\/or refractory multiple myeloma. Blood. https:\/\/doi.org\/10.1182\/blood-2016-01-694786","journal-title":"Blood"},{"key":"7825_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12835","author":"KM Abdulkadyrov","year":"2014","unstructured":"Abdulkadyrov KM, Salogub GN, Khuazheva NK et al (2014) Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.12835","journal-title":"Br J Haematol"},{"key":"7825_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13056","author":"SP Iyer","year":"2014","unstructured":"Iyer SP, Beck JT, Stewart AK et al (2014) A phase IB multicentre dose\u2010determination study of BHQ880 in combination with anti\u2010myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal\u2010related events. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.13056","journal-title":"Br J Haematol"},{"issue":"1","key":"7825_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11657-020-00825-1","volume":"15","author":"G Ogliari","year":"2020","unstructured":"Ogliari G, Lunt E, Ong T, Marshall L, Sahota O (2020) The impact of lockdown during the COVID-19 pandemic on osteoporotic fragility fractures: an observational study. Arch Osteoporos 15(1):156","journal-title":"Arch Osteoporos"},{"issue":"8","key":"7825_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/imj.13502","volume":"47","author":"OL Lee","year":"2017","unstructured":"Lee OL, Horvath N, Lee C et al (2017) Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Intern Med J 47(8):938\u201351","journal-title":"Intern Med J"},{"key":"7825_CR37","doi-asserted-by":"crossref","unstructured":"Camacho PM, Petak SM, Binkley N, et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u20142020 Update. Endocrine Practice. 26(Suppl 1):1-46.","DOI":"10.4158\/GL-2020-0524SUPPL"},{"issue":"3","key":"7825_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-020-05804-3","volume":"32","author":"WF Lems","year":"2021","unstructured":"Lems WF, Paccou J, Zhang J et al (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporosis International 32(3):399\u2013411","journal-title":"Osteoporosis International"},{"key":"7825_CR39","doi-asserted-by":"crossref","unstructured":"Wong RMY, Wong PY, Liu C, et al (2022) The imminent risk of a fracture\u2014existing worldwide data: a systematic review and meta-analysis. Osteoporosis Int 33(12):2453-2466.","DOI":"10.1007\/s00198-022-06473-0"},{"key":"7825_CR40","doi-asserted-by":"crossref","unstructured":"Whitfield E, White B, Barclay M, et al (2025) Differences in recording of cancer diagnosis between datasets in England: a population-based study of linked cancer registration, hospital, and primary care data - PubMed. Cancer epidemiology. 94:102703.","DOI":"10.1016\/j.canep.2024.102703"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07825-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:36:50Z","timestamp":1776245810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07825-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7825"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07825-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Independent Scientific Advisory Committee (ISAC) approved the study (ISAC protocol application number: 18_137) and given that only de-identified routinely collected data were used, no further approvals were required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"MTSS was supported by grants or contracts from the Oxford NIHR Musculoskeletal Biomedical Research Centre (BRC), and has received consultancy fees from Theramex. BK reports lecture fees and\/or consulting honoraria from Pfizer, Sanofi, and Janssen. KR has received grant funding to their institution from Janssen, Amgen, Takeda, GSK, Celegene\u2014Bristol Myers Squibb; honoraria from Janssen, Adaptive Biotech, Amgen, Takeda, AbbVie, Oncopeptides, Celgene \u2013 Bristol Myers Squibb, Pfizer, Recordati, and GSK; support for attending meetings and\/or travel from BMS, Amgen, and Takeda; is an advisor for Janssen, Adaptive Biotech, Amgen, Recordati, Takeda, AbbVie, Oncopeptides, Celgene \u2013 Bristol Myers Squibb, Pfizer, Menarini Stemline, and GSK. RPV has received grants or contracts from UCB, and lecture fees and\/or consulting honoraria from UCB, Amgen, and IOF. MKJ has received consulting fees from UCB, Nannox AI, Native Technologies Limited; honoraria from Amgen Ltd, Sanofi, UCB; support for attending meetings and\/or travel from UCB; and has a leadership or fiduciary role on the Royal Osteoporosis Society Clinical Research Committee. The remaining authors declare no conflicts of interest relevant to this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}